AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35818122 — intervention group
Group type: COMPARATOR
Intervention: Minimal arm (3 phone sessions + 2 weeks of nicotine patches)
Number of subjects: 818
Study 35818122 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive arm
Number of subjects: 818
Study 35818122 — intervention group
Group type: COMPARATOR
Intervention: Minimal arm
Number of subjects: 818
Study 34503597 — intervention group
Group type: EXPERIMENTAL
Intervention: Riceberry rice (RR)
Number of subjects: 6
Study 34503597 — intervention group
Group type: COMPARATOR
Intervention: White rice (WR)
Number of subjects: 6
Study 34964149 — intervention group
Group type: COMPARATOR
Intervention: Galantamine 16 mg
Number of subjects: 50
Study 33931415 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-led mobile health intervention
Number of subjects: 136
Study 33931415 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 136
Study 32374959 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular thrombectomy preceded by intravenous alteplase (0.9 mg/kg within 4.5 hours after symptom onset)
Number of subjects: 656
Study 32374959 — intervention group
Group type: COMPARATOR
Intervention: Endovascular thrombectomy alone
Number of subjects: 656
Study 32374959 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination-therapy group (thrombectomy with alteplase)
Number of subjects: 656
Study 34844423 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular thrombectomy (EVT) with computed tomography perfusion (CTP) imaging
Number of subjects: 1348
Study 34844423 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular thrombectomy (EVT) without computed tomography perfusion (CTP) imaging
Number of subjects: 1348
Study 34844423 — intervention group
Group type: COMPARATOR
Intervention: Best medical management (control group) with computed tomography perfusion (CTP) imaging
Number of subjects: 1348
Study 34844423 — intervention group
Group type: COMPARATOR
Intervention: Best medical management (control group) without computed tomography perfusion (CTP) imaging
Number of subjects: 1348
Study 33445505 — intervention group
Group type: EXPERIMENTAL
Intervention: Stretching with isometric contraction and instrument‐assisted soft tissue mobilization
Number of subjects: 21
Study 33445505 — intervention group
Group type: COMPARATOR
Intervention: Instrument‐assisted soft tissue mobilization
Number of subjects: 21
Study 33445505 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 21
Study 33060370 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg
Number of subjects: 441
Study 33060370 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg
Number of subjects: 441
Study 33060370 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 441
Study 35565845 — intervention group
Group type: EXPERIMENTAL
Intervention: Beet It Sport® alone
Number of subjects: 0
Study 35565845 — intervention group
Group type: EXPERIMENTAL
Intervention: Beet It Sport® plus 200 mg vitamin C
Number of subjects: 0
Study 35565845 — intervention group
Group type: EXPERIMENTAL
Intervention: Beet It Sport® plus 15 g of whey protein
Number of subjects: 0
Study 35565845 — intervention group
Group type: COMPARATOR
Intervention: Beet It Sport® (all treatments)
Number of subjects: 0
Study 34687316 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (500mg) with 12 months of antithyroid drug (ATD)
Number of subjects: 27
Study 34687316 — intervention group
Group type: EXPERIMENTAL
Intervention: B lymphocyte count at 28 weeks
Number of subjects: 27
Study 35108312 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer education based on adolescent health education (1-year duration)
Number of subjects: 1613
Study 35108312 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1613
Study 33073447 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 80
Study 33073447 — intervention group
Group type: EXPERIMENTAL
Intervention: Air‐abrasion before sintering (ABS)
Number of subjects: 80
Study 33073447 — intervention group
Group type: EXPERIMENTAL
Intervention: Air‐abrasion after sintering (AAS)
Number of subjects: 80
Study 33073447 — intervention group
Group type: EXPERIMENTAL
Intervention: Air‐abrasion before and after sintering (ABS + AAS)
Number of subjects: 80
Study 33073447 — intervention group
Group type: EXPERIMENTAL
Intervention: Fs laser before sintering (FBS)
Number of subjects: 80
Study 33073447 — intervention group
Group type: EXPERIMENTAL
Intervention: Fs laser before sintering + air‐abrasion after sintering (FBS + AAS)
Number of subjects: 80
Study 33073447 — intervention group
Group type: EXPERIMENTAL
Intervention: Fs laser after sintering (FAS)
Number of subjects: 80
Study 33073447 — intervention group
Group type: EXPERIMENTAL
Intervention: Fs laser after sintering + air‐abrasion after sintering (FAS + AAS)
Number of subjects: 80
Study 35439582 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive blood glucose control (hemoglobin A1c ≤6.5%)
Number of subjects: 682
Study 35439582 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive blood pressure control (combination of perindopril‐indapamide)
Number of subjects: 682
Study 35439582 — intervention group
Group type: COMPARATOR
Intervention: Standard blood glucose control (usual care)
Number of subjects: 682
Study 35439582 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for blood pressure control)
Number of subjects: 682
Study 34634101 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart team protocol for decision-making
Number of subjects: 101
Study 32217864 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxapine
Number of subjects: 0
Study 32217864 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 0
Study 32217864 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine
Number of subjects: 0
Study 32217864 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 0
Study 32217864 — intervention group
Group type: EXPERIMENTAL
Intervention: Mianserin
Number of subjects: 0
Study 32217864 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine
Number of subjects: 0
Study 32217864 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 0
Study 35701080 — intervention group
Group type: EXPERIMENTAL
Intervention: Grape-based training models (group A)
Number of subjects: 83
Study 35701080 — intervention group
Group type: COMPARATOR
Intervention: Virtual reality modulator and silicone suture pads (group B)
Number of subjects: 83
Study 33388987 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium‐competitive acid blocker (P‐CAB)
Number of subjects: 52
Study 33388987 — intervention group
Group type: EXPERIMENTAL
Intervention: Serotonin noradrenaline reuptake inhibitor (SNRI)
Number of subjects: 52
Study 32546262 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous antibiotics plus orally administered DBT for 10 days
Number of subjects: 0
Study 32546262 — intervention group
Group type: COMPARATOR
Intervention: Intravenous antibiotics plus placebo for 10 days
Number of subjects: 0
Study 32546262 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous antibiotics plus orally administered DBT
Number of subjects: 0
Study 32546262 — intervention group
Group type: COMPARATOR
Intervention: Intravenous antibiotics plus placebo
Number of subjects: 0
Study 35322978 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous bone marrow MSCs injection
Number of subjects: 0
Study 35322978 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 0
Study 33982093 — intervention group
Group type: EXPERIMENTAL
Intervention: DDD-CLS mode
Number of subjects: 20
Study 33982093 — intervention group
Group type: EXPERIMENTAL
Intervention: CLS responders
Number of subjects: 20
Study 32399578 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc oxide treatment
Number of subjects: 30
Study 32399578 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 30
Study 35072641 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavioral therapy (6 weekly sessions, with telephone support)
Number of subjects: 162
Study 35072641 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (control group)
Number of subjects: 162
Study 33255675 — intervention group
Group type: EXPERIMENTAL
Intervention: Harms messages
Number of subjects: 713
Study 33255675 — intervention group
Group type: EXPERIMENTAL
Intervention: Messages with harm or addiction content alone
Number of subjects: 713
Study 33255675 — intervention group
Group type: EXPERIMENTAL
Intervention: Flavor‐themed messages
Number of subjects: 713
Study 33255675 — intervention group
Group type: EXPERIMENTAL
Intervention: Social use‐themed messages
Number of subjects: 713
Study 35144952 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care plus intervention (SMS reminder messages to parents; reminders for their child’s GP from the hospital’s Paediatric Outpatients Department)
Number of subjects: 0
Study 35144952 — intervention group
Group type: COMPARATOR
Intervention: Standard care (hospital vaccine availability, ease of access and reminders for WCH subspecialists)
Number of subjects: 0
Study 33482007 — intervention group
Group type: EXPERIMENTAL
Intervention: Implicit motor learning walking intervention (analogy learning)
Number of subjects: 79
Study 33482007 — intervention group
Group type: COMPARATOR
Intervention: Explicit motor learning walking intervention (detailed verbal instructions)
Number of subjects: 79
Study 35463906 — intervention group
Group type: EXPERIMENTAL
Intervention: L:R (lactulose:rhamnose)
Number of subjects: 64
Study 35463906 — intervention group
Group type: COMPARATOR
Intervention: L:M (lactulose:mannitol)
Number of subjects: 64
Study 35463906 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating tTG IgA
Number of subjects: 64
Study 35106140 — intervention group
Group type: EXPERIMENTAL
Intervention: Pen
Number of subjects: 755
Study 35106140 — intervention group
Group type: EXPERIMENTAL
Intervention: Social incentive text cover letter
Number of subjects: 755
Study 35106140 — intervention group
Group type: COMPARATOR
Intervention: No pen
Number of subjects: 755
Study 35106140 — intervention group
Group type: COMPARATOR
Intervention: No social incentive text cover letter
Number of subjects: 755
Study 36126231 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 189
Study 36126231 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine Learning Algorithm (Gaussian Naïve Bayes)
Number of subjects: 189
Study 36126231 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline BEF and anxiety status
Number of subjects: 189
Study 32729586 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g intragastric tryptophan (Trp)
Number of subjects: 32
Study 32729586 — intervention group
Group type: COMPARATOR
Intervention: Volume-matched control
Number of subjects: 32
Study 35332216 — intervention group
Group type: EXPERIMENTAL
Intervention: e-TNS (verum)
Number of subjects: 538
Study 32163659 — intervention group
Group type: EXPERIMENTAL
Intervention: Immersive 3D interactive virtual reality (VR)
Number of subjects: 72
Study 32163659 — intervention group
Group type: COMPARATOR
Intervention: Control group (conventional anatomy training)
Number of subjects: 72
Study 36219307 — intervention group
Group type: EXPERIMENTAL
Intervention: Drawing attention to morphology group
Number of subjects: 36
Study 36219307 — intervention group
Group type: COMPARATOR
Intervention: Simple spelling exposure group
Number of subjects: 36
Study 35460310 — intervention group
Group type: EXPERIMENTAL
Intervention: Angelica gigas Nakai root extracts (ARE) lotion
Number of subjects: 0
Study 35460310 — intervention group
Group type: COMPARATOR
Intervention: Placebo lotion
Number of subjects: 0
Study 32007087 — intervention group
Group type: EXPERIMENTAL
Intervention: Stockholm Preterm Interaction-Based Intervention (SPIBI) - strengths-based early intervention programme with ten home visits and two telephone calls during the first year.
Number of subjects: 0
Study 32007087 — intervention group
Group type: COMPARATOR
Intervention: Standard follow-up and care plus extended assessment (Control group).
Number of subjects: 0
Study 36141917 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive radical hysterectomy
Number of subjects: 0
Study 36141917 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic-assisted radical hysterectomy
Number of subjects: 0
Study 36141917 — intervention group
Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 0
Study 34257146 — intervention group
Group type: EXPERIMENTAL
Intervention: Tonsillectomy and Adenoidectomy (T/A) within 2 months (eT/A)
Number of subjects: 117
Study 34257146 — intervention group
Group type: EXPERIMENTAL
Intervention: Tonsillectomy and Adenoidectomy (T/A) after the 12-month follow-up (T/A12)
Number of subjects: 117
Study 34012055 — intervention group
Group type: EXPERIMENTAL
Intervention: SENSE program (multisensory program)
Number of subjects: 70
Study 34012055 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care
Number of subjects: 70
Study 32911132 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer recovery support services (PRSS) intervention
Number of subjects: 80
Study 32911132 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 80
Study 35897370 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonazepam 0.5 mg for 4 weeks
Number of subjects: 60
Study 35897370 — intervention group
Group type: COMPARATOR
Intervention: Tongue protector for 4 weeks
Number of subjects: 60
Study 34551225 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA‐1273 vaccine (100 ?g)
Number of subjects: 30415
Study 34551225 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30415
Study 36007987 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolocumab (proprotein convertase subtilisin‐kexin type 9 inhibitor)
Number of subjects: 27564
Study 32776764 — intervention group
Group type: EXPERIMENTAL
Intervention: Prism adaptation
Number of subjects: 23
Study 32776764 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 23
Study 35958596 — intervention group
Group type: EXPERIMENTAL
Intervention: sIPV + DTaP concomitant administration
Number of subjects: 0
Study 35958596 — intervention group
Group type: COMPARATOR
Intervention: sIPV inoculation
Number of subjects: 0
Study 35958596 — intervention group
Group type: COMPARATOR
Intervention: DTaP inoculation
Number of subjects: 0
Study 33026154 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein (HP) diet with high intensity physical activity (HI)
Number of subjects: 2326
Study 33026154 — intervention group
Group type: COMPARATOR
Intervention: Moderate protein (MP) diet with moderate intensity physical activity (PA)
Number of subjects: 2326
Study 33026154 — intervention group
Group type: EXPERIMENTAL
Intervention: Low glycaemic index (GI) diet with high intensity physical activity (HI)
Number of subjects: 2326
Study 33026154 — intervention group
Group type: COMPARATOR
Intervention: Moderate protein (MP) diet with low glycaemic index (GI) and moderate intensity physical activity (PA)
Number of subjects: 2326
Study 32003357 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic rubber band ligation (Group B)
Number of subjects: 60
Study 32003357 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic injection sclerotherapy (Group A)
Number of subjects: 60
Study 36409223 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic supplementation
Number of subjects: 48
Study 36409223 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 33501972 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic prescribing at visits that met criteria (205/214)
Number of subjects: 425
Study 33501972 — intervention group
Group type: COMPARATOR
Intervention: Antibiotic prescribing at visits that did not meet criteria (193/211)
Number of subjects: 425
Study 35232533 — intervention group
Group type: EXPERIMENTAL
Intervention: Video Modelling (VM)
Number of subjects: 50
Study 35232533 — intervention group
Group type: COMPARATOR
Intervention: Picture Exchange Communication System (PECS)
Number of subjects: 50
Study 32229722 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehospital plasma
Number of subjects: 405
Study 33834628 — intervention group
Group type: EXPERIMENTAL
Intervention: Remibrutinib (0.5‒600 mg)
Number of subjects: 144
Study 33834628 — intervention group
Group type: EXPERIMENTAL
Intervention: Remibrutinib (>= 10 mg q.d.)
Number of subjects: 144
Study 33834628 — intervention group
Group type: EXPERIMENTAL
Intervention: Remibrutinib (>= 50 mg q.d.)
Number of subjects: 144
Study 33834628 — intervention group
Group type: EXPERIMENTAL
Intervention: Remibrutinib (>= 100 mg q.d.)
Number of subjects: 144
Study 33054828 — intervention group
Group type: EXPERIMENTAL
Intervention: Thorough information about adverse effects
Number of subjects: 51
Study 33054828 — intervention group
Group type: COMPARATOR
Intervention: Simple consent procedure
Number of subjects: 51
Study 36305961 — intervention group
Group type: EXPERIMENTAL
Intervention: Almonds (15% of energy requirement)
Number of subjects: 140
Study 36305961 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate-rich snack bar (isocaloric)
Number of subjects: 140
Study 32173730 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous Tranexamic Acid (TXA) 1-g dose prior to skin incision and another 1-g dose 4 hours later
Number of subjects: 44
Study 32173730 — intervention group
Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 44
Study 34187822 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment for MSF
Number of subjects: 0
Study 34187822 — intervention group
Group type: COMPARATOR
Intervention: Non-surgical treatment for MSF
Number of subjects: 0
Study 34187822 — intervention group
Group type: EXPERIMENTAL
Intervention: Text messages to maximise data collection and participant retention
Number of subjects: 0
Study 33157398 — intervention group
Group type: EXPERIMENTAL
Intervention: bare‐chested (fitspiration) images
Number of subjects: 300
Study 33157398 — intervention group
Group type: COMPARATOR
Intervention: clothed (fashion) images
Number of subjects: 300
Study 33157398 — intervention group
Group type: COMPARATOR
Intervention: scenery images
Number of subjects: 300
Study 33497293 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (6 mg · kg−1)
Number of subjects: 10
Study 33497293 — intervention group
Group type: COMPARATOR
Intervention: Placebo (cellulose)
Number of subjects: 10
Study 34096673 — intervention group
Group type: EXPERIMENTAL
Intervention: Glass-fibre post and composite resin core (Group F)
Number of subjects: 120
Study 34096673 — intervention group
Group type: EXPERIMENTAL
Intervention: Custom PEEK post-core (Group P)
Number of subjects: 120
Study 34096673 — intervention group
Group type: EXPERIMENTAL
Intervention: Custom zirconia post-core (Group Z)
Number of subjects: 120
Study 35429794 — intervention group
Group type: EXPERIMENTAL
Intervention: Distant ischemic postconditioning (DIPC)
Number of subjects: 86
Study 35429794 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 86
Study 34267511 — intervention group
Group type: EXPERIMENTAL
Intervention: Handheld expiratory flowmeter (Vitalograph Ltd., COPD‐6®, Ireland)
Number of subjects: 229
Study 34267511 — intervention group
Group type: COMPARATOR
Intervention: Conventional spirometry
Number of subjects: 229
Study 32087342 — intervention group
Group type: COMPARATOR
Intervention: self-monitoring (SM)
Number of subjects: 530
Study 32087342 — intervention group
Group type: EXPERIMENTAL
Intervention: self-monitoring + feedback (SM + FB)
Number of subjects: 530
Study 35946268 — intervention group
Group type: EXPERIMENTAL
Intervention: omega‐3 plus cetirizine
Number of subjects: 52
Study 35946268 — intervention group
Group type: COMPARATOR
Intervention: cetirizine
Number of subjects: 52
Study 36123569 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular blockade (NMB) agent
Number of subjects: 30
Study 33565308 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) with low dose prednisolone
Number of subjects: 37
Study 33565308 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine (CsA) with low dose prednisolone
Number of subjects: 37
Study 33303692 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile-based educational app
Number of subjects: 66
Study 33303692 — intervention group
Group type: COMPARATOR
Intervention: Standard medical management (control)
Number of subjects: 66
Study 33586783 — intervention group
Group type: EXPERIMENTAL
Intervention: 1X ST266
Number of subjects: 54
Study 33586783 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3X ST266
Number of subjects: 54
Study 33586783 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 54
Study 35767432 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional trance language (TTL)
Number of subjects: 178
Study 35767432 — intervention group
Group type: COMPARATOR
Intervention: Modern trance language (MTL)
Number of subjects: 178
Study 33440342 — intervention group
Group type: EXPERIMENTAL
Intervention: LT + SMS
Number of subjects: 32
Study 33440342 — intervention group
Group type: COMPARATOR
Intervention: LT
Number of subjects: 32
Study 32897386 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulation Choice Shared Decision Making tool
Number of subjects: 922
Study 32897386 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 922
Study 36044948 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-adhesive bulk-fill restorative (SABF, 3M)
Number of subjects: 30
Study 36044948 — intervention group
Group type: COMPARATOR
Intervention: Conventional bulk-fill composite (Filtek One, 3M; FOBF)
Number of subjects: 30
Study 34238026 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-eluting stents (DES)
Number of subjects: 600
Study 34238026 — intervention group
Group type: COMPARATOR
Intervention: Coronary-artery bypass grafting (CABG)
Number of subjects: 600
Study 35179709 — intervention group
Group type: EXPERIMENTAL
Intervention: AQCH 400 mg orally three times a day plus standard of care
Number of subjects: 210
Study 35179709 — intervention group
Group type: COMPARATOR
Intervention: Standard of care alone
Number of subjects: 210
Study 35935235 — intervention group
Group type: EXPERIMENTAL
Intervention: LTBI treatment (specific regimen not detailed)
Number of subjects: 100
Study 32789962 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional CPB with selective pulmonary artery perfusion (study group, n = 12)
Number of subjects: 24
Study 32789962 — intervention group
Group type: COMPARATOR
Intervention: Conventional CPB (control group, n = 12)
Number of subjects: 24
Study 34051293 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine 15mg daily at night for 8 weeks
Number of subjects: 120